Respiratory epithelial cells direct the initial inflammatory response in the cystic fibrosis (CF) lung, which is characterized by a massive influx of neutrophils into the airways. Once there, the neutrophils release proteases, like neutrophil elastase, into the airway lumen. The fact that elastase is a cause of lung damage in patients with CF has led to proposals for treatment with anti-proteases, yet the rests of clinical studies examining the use of the anti-protease have been disappointing. The systemic administration of anti-proteases is inefficient, and the concentrations delivered to the airway by the intravenous administration of the anti-protease are insufficient to inhibit the overwhelming amount of neutrophil elastase in the lung of patients with CF. Alternatively, inhaled anti-proteases are in homogeneously distributed in the CF lung, and these agents are trapped in the mucus layer which blocks the delivery to the epithelial surface. The ideal delivery system would permit the intravenous administration of an anti-protease, thus avoiding the barriers to aerosol delivery in the diseased lung, that specifically targets the lungs. One such approach would be to modify anti-protease by introducing a ligand that would target the airways via the polymeric immunoglobulin receptor (pIgR), which is designed for the efficient, non-degradative transfer of macromolecules across epithelial immunoglobulin receptor (pIgR), which is designed for the efficient, non-degradative transfer of macromolecules across epithelial surfaces. We have constructed recombinant fusion proteins consisting of an Rv fragment of anti-human secretory component linked to human alpha/1-antitrypsin (A/1AT), and have shown that protein conjugates consisting of antibody directed at the polymeric immunoglobulin receptor (pIgR) and A/1AT can be transported across epithelial cells in a basolateral-to-apical direction. This approach provides us with the ability to deliver therapeutic proteins, like A/1AT or secretory leukoprotease inhibitor, directly to the apical surface of the epithelium by targeting the pIgR with an appropriate ligand. This proposal is directed at determining the feasibility of transporting fusion proteins to the apical surface. We plan to refine this strategy by determining the optimal sequence of fusion proteins designed to accomplish this purpose, demonstrating the versatility of the approach by coupling other therapeutic proteins to the targeting ligand. We will also examine the transport of such fusions across cells that express the pIgR, and analyze the trafficking of the conjugates to determine whether the delivery of proteins to the luminal surface could be affected by co- treatment with the natural ligand or drugs. Finally, we will then use these reagents to examine the delivery of fusions and if bifunctitonal proteins can prevent the inflammatory response in rodent models. This proposal should allow us to better understand this method of protein delivery to the lung, and deserve further consideration as an alternative approach to therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL060293-05
Application #
6656534
Study Section
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
$263,865
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
van Heeckeren, Anna M; Schluchter, Mark D; Xue, Wei et al. (2006) Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med 173:288-96
Kube, Dianne M; Fletcher, David; Davis, Pamela B (2005) Relation of exaggerated cytokine responses of CF airway epithelial cells to PAO1 adherence. Respir Res 6:69
Waters, Valerie; Sokol, Sach; Reddy, Bharat et al. (2005) The effect of cyclosporin A on airway cell proinflammatory signaling and pneumonia. Am J Respir Cell Mol Biol 33:138-44
Van Heeckeren, Anna M; Scaria, Abraham; Schluchter, Mark D et al. (2004) Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection. Am J Physiol Lung Cell Mol Physiol 286:L717-26
Muir, Amanda; Soong, Grace; Sokol, Sach et al. (2004) Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am J Respir Cell Mol Biol 30:777-83
Gupta, Sanhita; Xie, Junxia; Ma, Jianjie et al. (2004) Intermolecular interaction between R domains of cystic fibrosis transmembrane conductance regulator. Am J Respir Cell Mol Biol 30:242-8
Adamo, Robert; Sokol, Sach; Soong, Grace et al. (2004) Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am J Respir Cell Mol Biol 30:627-34
van Heeckeren, Anna M; Schluchter, Mark; Xue, Lintong et al. (2004) Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice. Infect Immun 72:1479-86
van Heeckeren, Anna M; Schluchter, Mark D; Drumm, Mitchell L et al. (2004) Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 287:L944-52
Ferkol, Thomas; Cohn, Leah A; Phillips, Thomas E et al. (2003) Targeted delivery of antiprotease to the epithelial surface of human tracheal xenografts. Am J Respir Crit Care Med 167:1374-9

Showing the most recent 10 out of 18 publications